334 related articles for article (PubMed ID: 9926973)
41. Trichosporonosis.
Walsh TJ
Infect Dis Clin North Am; 1989 Mar; 3(1):43-52. PubMed ID: 2647833
[TBL] [Abstract][Full Text] [Related]
42. Trichosporon beigelii infection: experience in a regional burn center.
Cawley MJ; Braxton GR; Haith LR; Reilly KJ; Guilday RE; Patton ML
Burns; 2000 Aug; 26(5):483-6. PubMed ID: 10812273
[TBL] [Abstract][Full Text] [Related]
43. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes.
Pagano L; Antinori A; Ammassari A; Mele L; Nosari A; Melillo L; Martino B; Sanguinetti M; Equitani F; Nobile F; Carotenuto M; Morra E; Morace G; Leone G
Eur J Haematol; 1999 Aug; 63(2):77-85. PubMed ID: 10480286
[TBL] [Abstract][Full Text] [Related]
44. Trichosporon beigelii fungemia in patients with acute leukemia: report of three cases.
Hung CC; Chang SC; Chen YC; Tien HF; Hsieh WC
J Formos Med Assoc; 1995 Mar; 94(3):127-31. PubMed ID: 7613244
[TBL] [Abstract][Full Text] [Related]
45. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.
Atkinson BJ; Lewis RE; Kontoyiannis DP
Med Mycol; 2008 Sep; 46(6):541-6. PubMed ID: 19180749
[TBL] [Abstract][Full Text] [Related]
46. Summaries for patients. Itraconazole and amphotericin B to treat fungal infections in patients with cancer who are receiving chemotherapy.
Ann Intern Med; 2001 Sep; 135(6):S-39. PubMed ID: 11575279
[No Abstract] [Full Text] [Related]
47. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
Kibbler CC
Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
[TBL] [Abstract][Full Text] [Related]
48. Amphotericin B treatment of fungemia due to unusual pathogens in neutropenic patients: report of two cases.
Fanci R; Pecile P; Martinez RL; Fabbri A; Nicoletti P
J Chemother; 1997 Dec; 9(6):427-30. PubMed ID: 9491843
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice.
Kamberi P; Atsuro H; Takayoshi T; Masaru N
Chemotherapy; 1998; 44(1):55-62. PubMed ID: 9444410
[TBL] [Abstract][Full Text] [Related]
50. Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen.
Dabas Y; Xess I; Kale P
Med Mycol; 2017 Jul; 55(5):518-527. PubMed ID: 27816903
[TBL] [Abstract][Full Text] [Related]
51. Candida glabrata fungemia in a tertiary cancer institution in Slovakia.
Krcmery V; Krupova I; Mateicka F; Jurga L; Sulcova M; Spanik S; Kunová A; Novotny J
J Infect Chemother; 1999 Sep; 5(3):163-167. PubMed ID: 11810509
[TBL] [Abstract][Full Text] [Related]
52. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.
Anaissie EJ; Vartivarian SE; Abi-Said D; Uzun O; Pinczowski H; Kontoyiannis DP; Khoury P; Papadakis K; Gardner A; Raad II; Gilbreath J; Bodey GP
Am J Med; 1996 Aug; 101(2):170-6. PubMed ID: 8757357
[TBL] [Abstract][Full Text] [Related]
53. Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection.
Nucci M; Akiti T; Barreiros G; Silveira F; Revankar SG; Sutton DA; Patterson TF
J Clin Microbiol; 2001 Feb; 39(2):514-8. PubMed ID: 11158099
[TBL] [Abstract][Full Text] [Related]
54. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
55. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients.
Kovacicová G; Spánik S; Kunová A; Trupl J; Sabo A; Koren P; Sulcová M; Mateicka F; Novotný J; Pichnová E; Jurga L; Chmelík B; Obertik T; West D; Krcéry V
Scand J Infect Dis; 2001; 33(5):367-74. PubMed ID: 11440223
[TBL] [Abstract][Full Text] [Related]
56. [Prevention of fungal infections in children and adolescents with cancer].
Groll AH; Ritter J; Müller FM
Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
[TBL] [Abstract][Full Text] [Related]
57. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution.
Lass-Flörl C; Gunsilius E; Gastl G; Englisch M; Koch G; Ulmer H; Dierich MP; Petzer A
Ann Hematol; 2003 Sep; 82(9):565-9. PubMed ID: 14504812
[TBL] [Abstract][Full Text] [Related]
58. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
Antachopoulos C; Papakonstantinou E; Dotis J; Bibashi E; Tamiolaki M; Koliouskas D; Roilides E
J Pediatr Hematol Oncol; 2005 May; 27(5):283-5. PubMed ID: 15891566
[TBL] [Abstract][Full Text] [Related]
59. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
Matsue K; Uryu H; Koseki M; Asada N; Takeuchi M
Clin Infect Dis; 2006 Mar; 42(6):753-7. PubMed ID: 16477548
[TBL] [Abstract][Full Text] [Related]
60. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.
Buckler BS; Sams RN; Goei VL; Krishnan KR; Bemis MJ; Parker DP; Murray DL
Pediatr Infect Dis J; 2008 Aug; 27(8):762-4. PubMed ID: 18664989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
